MKI67 and neoplasm: Importantly, ROCKi led to loss of cell rounding and decreased Myosin II activity at IFs and DIFs (Fig. 6d, e), while a reduction of ki-67 positive cells was observed in all areas of ROCKi treated tumours (Fig. 6f).